Theravance Biopharma (TBPH) EBITDA (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of EBITDA data on file, last reported at -$9.5 million in Q1 2026.

• On a quarterly basis, EBITDA rose 34.3% year-over-year to -$9.5 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 102.69% increase from a year earlier, with the FY2025 full-year figure at -$3.6 million, up 92.33% from the prior year.
• EBITDA for Q1 2026 stood at -$9.5 million, down from $20.0 million in the prior quarter.
• Over the last five years, EBITDA for TBPH reached as high as $20.0 million in Q4 2025 and fell as low as -$38.5 million in Q1 2022.
• Historically, EBITDA has averaged -$12.2 million across 5 years, with a median of -$10.8 million in 2024.
• Across the five-year window, EBITDA slumped 47.44% in 2024 and soared 317.52% in 2025, its largest moves.
• Year by year, EBITDA stood at -$17.4 million in 2022, then jumped by 64.2% to -$6.2 million in 2023, then plunged by 47.44% to -$9.2 million in 2024, then surged by 317.52% to $20.0 million in 2025, then sank by 147.39% to -$9.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$9.5 million in Q1 2026, $20.0 million in Q4 2025, and -$6.5 million in Q3 2025.